Terlipressin
- Generic Name
- Terlipressin
- Brand Names
- Terlivaz
- Drug Type
- Biotech
- CAS Number
- 14636-12-5
- Unique Ingredient Identifier
- 7Z5X49W53P
- Background
Terlipressin is a synthetic analogue of vasopressin, which is an endogenous neurohormone that acts as a vasoconstrictor. It is a prodrug of lypressin, or lysine vasopressin. Compared to endogenous vasopressin, terlipressin has a longer half life and increased selectivity for the V1 receptor. As a potent vasopressor, terlipressin has been investigated in various shock states and conditions with diminished vasomotor tone. It was also studied in hepatorenal syndrome (HRS) and variceal bleeding. The drug was first approved by the FDA in September 2022.
- Indication
Terlipressin is a vasopressin receptor agonist indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function. The US prescribing information states that patients with a serum creatinine > 5 mg/dL are unlikely to experience benefit from terlipressin.
- Associated Conditions
- Hepato-Renal Syndrome, Hepatorenal Syndrome Type 1, Oesophageal varices haemorrhage, Portal Hypertension
The Effect of Terlipressin on Intesitnal Function in Septic Shock Patients
- First Posted Date
- 2014-12-03
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Liu ZiMeng
- Target Recruit Count
- 40
- Registration Number
- NCT02306239
- Locations
- 🇨🇳
the First Affiliated Hospital of Sumyetsan University, Guangzhou, Guangdong, China
Hemodynamic Effects of Terlipressin and High Dose Octreotide
- Conditions
- Gastric and Esophageal Varices
- Interventions
- First Posted Date
- 2014-04-22
- Last Posted Date
- 2016-06-13
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 88
- Registration Number
- NCT02119884
- Locations
- 🇨🇳
180 Fenglin Road, Shanghai, Shanghai, China
Perioperative Evaluation of Terlipressin Infusion During Living Donor Liver Transplantation on Incidence of Acute Kidney
- Conditions
- Acute Kidney InjuryLiver TransplantationTerlipressinNGAL
- Interventions
- Drug: placebo
- First Posted Date
- 2014-02-11
- Last Posted Date
- 2016-12-15
- Lead Sponsor
- National Liver Institute, Egypt
- Target Recruit Count
- 25
- Registration Number
- NCT02059460
- Locations
- 🇪🇬
National Liver Institute, Shebeen Alkom, Menoufiya, Egypt
Treatment of Type-1 Hepatorenal Syndrome Associated With Sepsis
- First Posted Date
- 2013-08-30
- Last Posted Date
- 2013-09-05
- Lead Sponsor
- Hospital Clinic of Barcelona
- Target Recruit Count
- 18
- Registration Number
- NCT01932151
- Locations
- 🇪🇸
Hospital Clinic de Barcelona, Barcelona, Spain
Terlipressin Administration in Patients Undergoing Major Liver Resection
- First Posted Date
- 2013-08-14
- Last Posted Date
- 2018-03-29
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Target Recruit Count
- 150
- Registration Number
- NCT01921985
- Locations
- 🇨🇭
Dep. of Visceral Surgery, University Hospital Berne, Berne, Switzerland
Efficacy and Safety of Monotherapy With Noradrenaline and Terlipressin in Patients of Cirrhosis With Septic Shock Admitted to Intensive Care Unit
- Conditions
- Cirrhosis With Septic Shock
- Interventions
- First Posted Date
- 2013-04-19
- Last Posted Date
- 2016-11-22
- Lead Sponsor
- Institute of Liver and Biliary Sciences, India
- Target Recruit Count
- 84
- Registration Number
- NCT01836224
- Locations
- 🇮🇳
Institute of liver and Biliary Sciences, New Delhi, Delhi, India
Continuos Terlipressin Infusion in Septic Shock
- First Posted Date
- 2012-10-02
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
- Target Recruit Count
- 1000
- Registration Number
- NCT01697410
- Locations
- 🇨🇳
Surgical intensive care unit, 1st affiliated hospital of Sun Yat-sen university, Guangzhou, Guangdong, China
An Exploratory Haemodynamic Study in Patients With Compensated Cirrhosis and Portal Hypertension
- Conditions
- Compensated Cirrhosis and Portal Hypertension
- Interventions
- First Posted Date
- 2012-07-16
- Last Posted Date
- 2016-03-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 47
- Registration Number
- NCT01640964
- Locations
- 🇬🇧
Novartis Investigative Site, Edinburgh, United Kingdom
TYPE 2 HEPATORENAL SYNDROME
- Conditions
- Safety and Efficacy of Terlipressin and Noradrenaline and Predictive Factors of Response in Type 2 HRS
- Interventions
- First Posted Date
- 2012-07-11
- Last Posted Date
- 2012-07-11
- Lead Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
- Target Recruit Count
- 46
- Registration Number
- NCT01637454
- Locations
- 🇮🇳
Postgraduate Institute of Medical Education and Research Chandigarh, Chandigarh, India
Treatment of Hepatorenal Syndrome With Terlipressin Infusion Adjusted to Hemodynamic Response
- First Posted Date
- 2012-02-10
- Last Posted Date
- 2016-08-18
- Lead Sponsor
- Pere Gines
- Target Recruit Count
- 40
- Registration Number
- NCT01530711
- Locations
- 🇪🇸
Hospital Moisés Broggi, Sant Joan Despí, Barcelona, Spain
🇪🇸Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
🇪🇸Hospital Vall d´Hebron, Barcelona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.